New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2013
06:03 EDTGENEGenetic Technologies provides U.S. patent re-examination update
Genetic Technologies announced that the USPTO has now issued an action reaffirming the validity of certain claims contained in the Company's U.S. Patent No. 5,612,179 directed to non-coding DNA. As announced by the Company on July 9, 2012, Genetic Technologies had received formal notification from the USPTO that it had received and granted a request for ex parte re-examination of claims 1-18 and 26-32 of the '179 patent based upon a submission by Merial of Duluth, Georgia. Merial is currently a defendant in an action originally brought by the company in Colorado, USA for infringement of the '179 patent. That action currently is pending in Delaware Federal District Court.
News For GENE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:18 EDTGENEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Morgan Stanley (MS), up 2.1%... Cliffs Natural (CLF), up 1.3%... Check Point Software (CHKP), up 1.1%. ALSO HIGHER: Genetic Technologies (GENE), up 28.2% after additional health centers to offer BREVAGenplus... Hanwha Q Cells (HQCL), up 16.2% following solar module supply agreement with NextEra Energy (NEE)... Provectus (PVCT), up 6.7% after receiving notice of allowance for PV-10 combined with other drugs. DOWN AFTER EARNINGS: Royal Caribbean (RCL), down 6.1%... FARO (FARO), down 16.4%. ALSO LOWER: Yandex (YNDX), down after Barron's recommends that investors take some profits... Carnival (CCL), down 2% after Royal Caribbean reported quarterly results.
05:33 EDTGENEGenetic Technologies announces additional health centers to offer BREVAGenplus
Genetic Technologies announced that a further two new breast health centres will begin to offer BREVAGenplus to their at-risk patients in a systematic fashion. This is in addition to the six breast health centres that the company previously announced were set to adopt BREVAGenplus, of which all six have in fact provided samples during the March 2015 quarter. The company reiterates that it expects sales growth to accelerate in the second half of calendar 2015 and beyond. The company believes that the adoption of BREVAGenplus by a total of eight new breast health centres validates the company's recently re-focused sales and marketing strategy, announced in September 2014, whereby the Company shifted its focus to these large facilities. While these centres are more complex entities with longer sales cycles, they offer higher and more stable long-term revenue potential. The company is working closely with these pivotal breast health centres and referring health care practitioners to ensure the creation of a personalised comprehensive breast cancer risk assessment approach in which BREVAGenplus plays an integral role. In this way, the company aims to reinforce the benefits of the test, ease its adoption by the new clinics and ensure its routine use by them.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use